Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report

被引：81

作者：

Gertz, Morie A. ^{[1
]}

Lacy, Martha Q. ^{[1
]}

Dispenzieri, Angela ^{[1
]}

Hayman, Suzanne R. ^{[1
]}

Kumar, Shaji K. ^{[1
]}

Dingli, David ^{[1
]}

Ansell, Stephen M. ^{[1
]}

Gastineau, Dennis A. ^{[1
]}

Inwards, David J. ^{[1
]}

Johnston, Patrick B. ^{[1
]}

Litzow, Mark R. ^{[1
]}

Micallef, Ivana N. M. ^{[1
]}

Porrata, Luis F. ^{[1
]}

Leung, Nelson ^{[2
]}

Hogan, William J. ^{[1
]}

Buadi, Francis K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN 55905 USA

来源：

LEUKEMIA & LYMPHOMA | 2010年 / 51卷 / 12期

关键词：

Amyloidosis; multiple myeloma; nephrotic syndrome; restrictive cardiomyopathy; stem cell transplant; PRIMARY SYSTEMIC AMYLOIDOSIS; HIGH-DOSE MELPHALAN; BRAIN NATRIURETIC PEPTIDE; AL AMYLOIDOSIS; CARDIAC AMYLOIDOSIS; MULTIPLE-MYELOMA; GROWTH-FACTOR;

D O I：

10.3109/10428194.2010.524329

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-dose chemotherapy for the management of immunoglobulin light chain amyloidosis remains an effective and viable treatment technique for selected patients with this disorder. We reviewed the medical records of 434 patients uniformly treated with high-dose chemotherapy and autologous stem cell transplant at Mayo Clinic, Rochester, Minnesota, between 8 March 1996 and 13 April 2010. Outcomes, engraftment, and predictors of early mortality were reviewed. Median survival has not been reached for the patients with a complete response, is 107 months for those with a partial response, and is 32 months for patients with no response (p < 0.001). The only predictor of survival was cardiac stage (p < 0.001). The hematologic response rate is predictive for organ response rates. Both hematologic and organ responses are associated with improved survival.</.

引用

页码：2181 / 2187

页数：7

共 25 条

[1] Systemic immunoglobulin light-chain amyloidosis [J].

Comenzo, Raymond L. .

CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (03) :182-185

[2] Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis [J].

Connors, Lawreen H. ;

Prokaeva, Tatiana ;

Lim, Amareth ;

Theberge, Roger ;

Falk, Rodney H. ;

Doros, Gheorghe ;

Berg, Alan ;

Costello, Catherine E. ;

O'Hara, Carl ;

Seldin, David C. ;

Skinner, Martha .

AMERICAN HEART JOURNAL, 2009, 158 (04) :607-614

[3] Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation [J].

Dispenzieri, A ;

Lacy, MQ ;

Katzmann, JA ;

Rajkumar, SV ;

Abraham, RS ;

Hayman, SR ;

Kumar, SK ;

Clark, R ;

Kyle, RA ;

Litzow, MR ;

Inwards, DJ ;

Ansell, SM ;

Micallef, IM ;

Porrata, LF ;

Elliott, MA ;

Johnston, PB ;

Greipp, PR ;

Witzig, TE ;

Zeldenrust, SR ;

Russell, SJ ;

Gastineau, D ;

Gertz, MA .

BLOOD, 2006, 107 (08) :3378-3383

[4] Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis [J].

Dispenzieri, A ;

Gertz, MA ;

Kyle, RA ;

Lacy, MQ ;

Burritt, MF ;

Therneau, TM ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Rajkumar, SV ;

Fonseca, R ;

Zeldenrust, SR ;

McGregor, CGA ;

Jaffe, AS .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) :3751-3757

[5] Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL) [J].

Gertz, M. A. ;

Lacy, M. Q. ;

Dispenzieri, A. ;

Hayman, S. R. ;

Kumar, S. K. ;

Leung, N. ;

Gastineau, D. A. .

BONE MARROW TRANSPLANTATION, 2007, 40 (10) :989-993

[6] Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma [J].

Gertz, M. A. ;

Kumar, S. K. ;

Lacy, M. Q. ;

Dispenzieri, A. ;

Hayman, S. R. ;

Buadi, F. K. ;

Dingli, D. ;

Gastineau, D. A. ;

Winters, J. L. ;

Litzow, M. R. .

BONE MARROW TRANSPLANTATION, 2009, 43 (08) :619-625

[7] Amyloidosis [J].

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Hayman, SR .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :709-727

[8] Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate [J].

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Ansell, SM ;

Elliott, MA ;

Gastineau, DA ;

Inwards, DJ ;

Micallef, INM ;

Porrata, LF ;

Tefferi, A ;

Litzow, MR .

BONE MARROW TRANSPLANTATION, 2004, 34 (12) :1025-1031

[9] Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis [J].

Gertz, MA ;

Comenzo, R ;

Falk, RH ;

Fermand, JP ;

Hazenberg, BP ;

Hawkins, PN ;

Merlini, G ;

Moreau, P ;

Ronco, P ;

Sanchorawala, V ;

Sezer, O ;

Solomon, A ;

Grateau, G .

AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (04) :319-328

[10] Autologous stem cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative [J].

Gertz, Morfe A. ;

Ansell, Stephen M. ;

Dingli, David ;

Dispenzieri, Angela ;

Buadi, Francis K. ;

Elliott, Michelle A. ;

Gastineau, Dennis A. ;

Hayman, Suzanne R. ;

Hogan, William J. ;

Inwards, David J. ;

Johnston, Patrick B. ;

Kumar, Shaji ;

Lacy, Martha Q. ;

Leung, Nelson ;

Micallef, Ivana N. M. ;

Porrata, Luis F. ;

Schafer, Barbara A. ;

Wolf, Robert C. ;

Litzow, Mark R. .

MAYO CLINIC PROCEEDINGS, 2008, 83 (10) :1131-1135

← 1 2 3 →